These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 17266941

  • 1. Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma.
    Huether A, Höpfner M, Baradari V, Schuppan D, Scherübl H.
    Biochem Pharmacol; 2007 May 01; 73(9):1308-17. PubMed ID: 17266941
    [Abstract] [Full Text] [Related]

  • 2. Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells.
    Jane EP, Premkumar DR, Pollack IF.
    J Pharmacol Exp Ther; 2006 Dec 01; 319(3):1070-80. PubMed ID: 16959960
    [Abstract] [Full Text] [Related]

  • 3. The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours.
    Höpfner M, Baradari V, Huether A, Schöfl C, Scherübl H.
    Endocr Relat Cancer; 2006 Mar 01; 13(1):135-49. PubMed ID: 16601284
    [Abstract] [Full Text] [Related]

  • 4. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
    Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C.
    Cancer Res; 2006 Dec 15; 66(24):11851-8. PubMed ID: 17178882
    [Abstract] [Full Text] [Related]

  • 5. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
    Ulivi P, Arienti C, Amadori D, Fabbri F, Carloni S, Tesei A, Vannini I, Silvestrini R, Zoli W.
    J Cell Physiol; 2009 Jul 15; 220(1):214-21. PubMed ID: 19288493
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.
    Adnane L, Trail PA, Taylor I, Wilhelm SM.
    Methods Enzymol; 2006 Jul 15; 407():597-612. PubMed ID: 16757355
    [Abstract] [Full Text] [Related]

  • 9. Helicobacter pylori and mitogen-activated protein kinases regulate the cell cycle, proliferation and apoptosis in gastric epithelial cells.
    Ding SZ, Smith MF, Goldberg JB.
    J Gastroenterol Hepatol; 2008 Jul 15; 23(7 Pt 2):e67-78. PubMed ID: 18702686
    [Abstract] [Full Text] [Related]

  • 10. Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells.
    Takezawa K, Okamoto I, Yonesaka K, Hatashita E, Yamada Y, Fukuoka M, Nakagawa K.
    Cancer Res; 2009 Aug 15; 69(16):6515-21. PubMed ID: 19638574
    [Abstract] [Full Text] [Related]

  • 11. Multikinase inhibitor sorafenib exerts cytocidal efficacy against Non-Hodgkin lymphomas associated with inhibition of MAPK14 and AKT phosphorylation.
    Chapuy B, Schuelper N, Panse M, Dohm A, Hand E, Schroers R, Truemper L, Wulf GG.
    Br J Haematol; 2011 Feb 15; 152(4):401-12. PubMed ID: 21689083
    [Abstract] [Full Text] [Related]

  • 12. Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation.
    Plastaras JP, Kim SH, Liu YY, Dicker DT, Dorsey JF, McDonough J, Cerniglia G, Rajendran RR, Gupta A, Rustgi AK, Diehl JA, Smith CD, Flaherty KT, El-Deiry WS.
    Cancer Res; 2007 Oct 01; 67(19):9443-54. PubMed ID: 17909054
    [Abstract] [Full Text] [Related]

  • 13. Effective treatment of advanced cholangiocarcinoma by hepatic arterial infusion chemotherapy combination with sorafenib: one case report from China.
    Qun W, Tao Y.
    Hepatogastroenterology; 2010 Oct 01; 57(99-100):426-9. PubMed ID: 20698202
    [Abstract] [Full Text] [Related]

  • 14. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
    Kurosu T, Ohki M, Wu N, Kagechika H, Miura O.
    Cancer Res; 2009 May 01; 69(9):3927-36. PubMed ID: 19366808
    [Abstract] [Full Text] [Related]

  • 15. Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials.
    Takimoto CH, Awada A.
    Cancer Chemother Pharmacol; 2008 Apr 01; 61(4):535-48. PubMed ID: 18026728
    [Abstract] [Full Text] [Related]

  • 16. Activation of the RAF/mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway mediates apoptosis induced by chelerythrine in osteosarcoma.
    Yang R, Piperdi S, Gorlick R.
    Clin Cancer Res; 2008 Oct 15; 14(20):6396-404. PubMed ID: 18927278
    [Abstract] [Full Text] [Related]

  • 17. Antiproliferative and proapoptotic effects of histone deacetylase inhibitors on gastrointestinal neuroendocrine tumor cells.
    Baradari V, Huether A, Höpfner M, Schuppan D, Scherübl H.
    Endocr Relat Cancer; 2006 Dec 15; 13(4):1237-50. PubMed ID: 17158768
    [Abstract] [Full Text] [Related]

  • 18. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma.
    Wang Z, Zhou J, Fan J, Qiu SJ, Yu Y, Huang XW, Tang ZY.
    Clin Cancer Res; 2008 Aug 15; 14(16):5124-30. PubMed ID: 18698030
    [Abstract] [Full Text] [Related]

  • 19. Effect of epidermal growth factor receptor inhibitor alone and in combination with cisplatin on growth of vulvar cancer cells.
    Kim SH, Song YC, Kim SH, Jo H, Song YS.
    Ann N Y Acad Sci; 2009 Aug 15; 1171():642-8. PubMed ID: 19723115
    [Abstract] [Full Text] [Related]

  • 20. EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer.
    Huether A, Höpfner M, Baradari V, Schuppan D, Scherübl H.
    Biochem Pharmacol; 2005 Nov 25; 70(11):1568-78. PubMed ID: 16226226
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.